In my career as a neurologist, I have encountered a wide range of rare, devastating neurodegenerative and neurometabolic diseases, many of which have no approved treatment options....

The advent of potentially curative gene therapies – particularly for use in rare disease – is rapidly shifting society’s perspective on medicine, as well as the vital role that pat...

On behalf of the whole team at Orchard, I would like to extend a humble thank you to all those that have participated in the MLD gene therapy clinical development program and to th...

As we celebrate Orchard’s five-year anniversary this September, I flash back to when I sat together at a coffee shop with my good friend and colleague, Nicolas Koebel, to start sha...

I’ve always felt strongly about the power in collaboration and connections to drive growth. When I joined Orchard as VP, Global Head of Pharmacovigilance in January 2020, I was ini...

In my last post, I shared my perspective on the overall field of gene therapy and the distinctive characteristics of the hematopoietic stem cell (HSC) gene therapy approach that Or...